Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

Avutometinib plus defactinib granted priority review by FDA, under the accelerated approval pathway ... tyrosine kinases. FAK and Pyk2 integrate signals from integrin and growth factor receptors ...

under the accelerated approval pathway and granted Priority Review for avutometinib, an oral RAF/MEK clamp, in combination with defactinib, an oral, selective FAK inhibitor, in adult patients with ...

In addition to adhesion, αV integrin promotes the activation of a multitude of signaling pathways, primarily the FAK pathway (116). The phosphorylation of FAK will in turn recruit Src kinases, ...

We investigated the therapeutic potential of targeting integrin/FAK-dependent signaling, an adhesion receptor-mediated pathway that has been increasingly linked to non-small cell lung cancer (NSCLC) ...